Trivaris (Triamcinolone Acetonide Injectable Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 16, 2016 Category: Drugs & Pharmacology Source Type: news
Clearside Biomedical launches trial for Zuprata
Clearside Biomedical (NSDQ:CLSD) said today that it enrolled the 1st patient in clinical trial of its suspension formulation of corticosteroid triamcinolone acetonide, Zuprata, for the treatment of diabetic macular edema.
The Alpharetta, Ga.-based company’s Hulk Phase I/II trial is an open-label, multi-center study designed to evaluate the safety and efficacy Zuprata administered in the suprachoroidal space along with intravitreal aflibercept and as an independent therapy in patients with diabetic macular edema. The trial is slated to enroll 20 patients with equal participation in both arms. Anatomical and function...
Source: Mass Device - November 15, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Diabetes Drug-Device Combinations Optical/Ophthalmic Clearside Biomedical Source Type: news
Clearside Biomedical names VP business development | Personnel Moves, Nov. 8, 2016
Clearside Biomedical (NSDQ:CLSD) today named Rick McElheny as its VP of business development.
The Alpharetta, Ga.-based company is developing a microinjector loaded with CLS-TA (triamcinolone acetonide) to treat macular edema. The device is designed to inject the compound in the a 30-µm gap between the choroid and the sclera, called the suprachoroidal space. A pivotal Phase III trial of the treatment is under way.
Get the full story at our sister site, Drug Delivery Business News.
The post Clearside Biomedical names VP business development | Personnel Moves, Nov. 8, 2016 appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 8, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Optical/Ophthalmic Clearside Biomedical Johnson & Johnson Personnel Moves Source Type: news
Nystatin and Triamcinolone Acetonide (Nystatin and Triamcinolone Acetonide Cream, Ointment) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 6, 2016 Category: Drugs & Pharmacology Source Type: news
Triamcinolone Hexacetonide Injectable Suspension (Aristospan) (Updated - Discontinuation)
Updated Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - August 30, 2016 Category: Drugs & Pharmacology Source Type: news
Glenmark gets FDA nod for skin ointment
< a href="http://economictimes.indiatimes.com/industry/healthcare/biotech/glenmark-gets-fda-nod-for-skin-ointment/articleshow/53375602.cms" > < img width="100" height="75" border="0" hspace="10" align="left" src="http://img.etimg.com/photo/53375602.cms" / > < /a > Approval has been granted for generic version of triamcinolone acetonide ointment USP, 0.5 per cent of Perrigo New York, Inc. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 25, 2016 Category: Pharmaceuticals Source Type: news
Teligent, Inc. Receives Two FDA Approvals For Topical Prescription Portfolio
Represent the Fifth and Sixth FDA Approvals of the Year, Launches Planned for This Quarter
BUENA, N.J., July 8, 2016 -- (Healthcare Sales & Marketing Network) -- Teligent, Inc. (TLGT), a New Jersey-based specialty generic pharmaceutical company, announ... Biopharmaceuticals, Generics, FDATeligent, Triamcinolone Acetonide (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 8, 2016 Category: Pharmaceuticals Source Type: news
Glenmark gets USFDA final nod for anti-fungal ointment
Glenmark Pharmaceuticals Inc has been granted final approval by the US Food and Drug Administration (USFDA) for nystatin and triamcinolone acetonide ointment. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 24, 2016 Category: Pharmaceuticals Source Type: news
Clearside Biomedical floats $50m IPO
Clearside Biomedical raised $50 million with its initial public offering, floating 7.2 million shares at $7 apiece.
That’s below the range Clearside earlier set for the IPO, when it planned to put up 4.0 million shares at a range of $14 to $16, for a midpoint value of $60 million.
Alpharetta, Ga.-based Clearside is developing a drug-device combination to treat macular edema using CLS-TA triamcinolone acetonide and its SCS microinjector. The device is designed to inject the compound in the suprachoroidal space, the 30-µm gap between the choroid and the sclera. A Phase III trial of the CLS-TA treatment is un...
Source: Mass Device - June 2, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Drug-Device Combinations Funding Roundup Initial Public Offering (IPO) Optical/Ophthalmic Clearside Biomedical Source Type: news
Trianex (Triamcinolone Acetonide Ointment) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 21, 2016 Category: Drugs & Pharmacology Source Type: news
Anika Therapeutics wins CE Mark for Cingal knee treatment
Anika Therapeutics said today it won CE Mark approval in the European Union for its Cingal drug-combo designed to treat osteoarthritis-related knee pain.
Cingal is a combined viscosupplement formulated with the company’s cross-linked sodium hyaluronate and triamcinolone hexacetonide, a steroid used to treat inflammation, the Bedford, Mass.-based company said.
“The European approval of Cingal marks an important milestone for Anika as it advances our global expansion strategy, provides a platform for us to demonstrate our commercialization capabilities, and most importantly, reinforces the product’s tremendous cli...
Source: Mass Device - March 28, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Drug-Device Combinations Orthopedics Regulatory/Clearance Anika Therapeutics Inc. Source Type: news
Advantages Claimed for Dropless Cataract SurgeryAdvantages Claimed for Dropless Cataract Surgery
Use of a combined triamcinolone/moxifloxacin compound improves therapeutic compliance, enhances prophylaxis against infection, and costs less than conventional eyedrops. Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 21, 2015 Category: Consumer Health News Tags: Ophthalmology Article Source Type: news
Anika assigned to FDA’s drug eval arm for Cingal approval
Anika Therapeutics today said the FDA’s Office of Combination Products assigned the company’s Cingal drug-combo to its Center for Drug Evaluation and Research arm to pursue premarket regulatory approval.
Cingal is a combined viscosupplement formulated with the company’s cross-linked sodium hyaluronate and triamcinolone hexacetonide, a steroid used to treat inflammation, the company said.
“While we strongly disagree with the FDA’s decision, as our position of Cingal’s device-lead classification is supported by both regulations and scientific data, we intend to proceed expeditiously to move Cingal...
Source: Mass Device - December 9, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Drug-Device Combinations Pre-Market Approval (PMA) Food & Drug Administration (FDA) Regulatory/Compliance Anika Therapeutics Inc. Source Type: news
Clearside Biomedical raises $14.4m, enrolls 1st patient in Phase III trial
Clearside Biomedical raised $14.4 million in a new round of equity financing, and said yesterday it enrolled the 1st patient in the Phase 3 Peachtree clinical trial of its CLS-TA for treating patients with macular edema associated with non-infectious uveitis.
Clearside is developing CLS-TA triamcinolone acetonide to be delivered using its proprietary SCS microinjector for patients with macular adema. The device is designed to inject the compound in the suprachoroidal space, a gap no wider than 30 µm between the choroid and the sclera that extends from the anterior portion of the eye to the posterior near the optic nerve...
Source: Mass Device - December 8, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Optical/Ophthalmic Drug-Device Combinations Business/Financial News Clearside Biomedical Source Type: news
Clearside closes patient enrolment in Phase II Dogwood trial of CLS-TA to treat macular edema
US clinical-stage biopharmaceutical firm Clearside Biomedical has completed patient enrolment in its Phase II clinical trial (Dogwood) of CLS-TA, its proprietary form of triamcinolone acetonide, to treat macular edema associated with non-infectious u… (Source: Drug Development Technology)
Source: Drug Development Technology - October 12, 2015 Category: Pharmaceuticals Source Type: news
